ASCO 2025 | A Phase I study of asciminib combined with dasatinib, prednisone, and blinatumomab for Ph+ ALL
Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, discusses a Phase I study (NCT03595917) that investigated the use of dasatinib, asciminib, blinatumomab, and prednisone in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Dr Luskin highlights that the results with this dual tyrosine kinase inhibitor (TKI) approach were encouraging, and she shares her excitement at the potential of providing patients with a chemotherapy-free and transplant-free therapeutic option. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I’m really excited to present some initial results from the trial being conducted by our center, exploring the use of a dual TKI approach with dasatinib, asciminib, and with the addition of blinatumomab for Philadelphia chromosome positive ALL. Our group has been working on this effort for some time now, and we have previously published our experience treating patients with the combination of dasatinib and asciminib which allows us to target the BCR-ABL lesion in this disease by binding at two different spots on the driver protein...
I’m really excited to present some initial results from the trial being conducted by our center, exploring the use of a dual TKI approach with dasatinib, asciminib, and with the addition of blinatumomab for Philadelphia chromosome positive ALL. Our group has been working on this effort for some time now, and we have previously published our experience treating patients with the combination of dasatinib and asciminib which allows us to target the BCR-ABL lesion in this disease by binding at two different spots on the driver protein. And this is supported by preclinical evidence, and we’re encouraged by our initial clinical experience. This may allow patients to achieve a deeper and more durable remissions by preventing escape pathways.
Historically, patients with Ph-positive ALL have moved from TKI-based induction with or without chemotherapy to transplantation. But now we have blinatumomab, which we’ve gotten more experience using this regimen, or using this agent as a consolidation strategy. This is really exciting because it’s an immunotherapy and it spares patients the toxicity of intensive chemotherapy and transplant. And so as that field’s developed, we’re really excited to now bring that therapy in combination with our dual TKI therapy to offer patients a chemotherapy-free, transplant-free, in some cases, approach to their treatment.
And so we are presenting our initial 15-patient safety cohort where we’ll be showing that this is a really tolerable regimen with really encouraging efficacy. And we’re really excited to further explore this regimen with more patients in the coming years with further improvements in the regimen, including optimizing the doses. So it’s really exciting. We think this is a really effective strategy, and we’ll also be highlighting the safety of the strategy. In particular, we are not seeing concerning issues with cardiovascular toxicity seen with the novel TKIs. So we’re really excited to present our findings and keep working on this project for the benefit of our patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Research Funding to Institution: Novartis, AbbVie; Advisory Boards: Jazz, Kite, Pfizer, Novartis; Consulting: Novartis.
